Local level biosimilar prescribing proactivity revealed in Italy

Biosimilars/Research | Posted 25/06/2021 post-comment0 Post your comment

Italian local healthcare authorities are highly proactive regarding actions on prescribing behaviour for off-patent biologicals, reveals a study published in GaBI Journal [1]. However, work needs to be done to appropriately reallocate resources gained through patent expiration. 

Clinician indications V17A13

The first biosimilar was approved by the European Medicines Agency in 2006. Since then, diverse policies aimed at increasing the use of biosimilars in clinical practice have been implemented at the national, regional and local level in Europe. It has been shown that these can lead to differences in uptake and related savings within a country. Authors Bertolani and Jommi found that most studies related to this focus on interchangeability and substitutability recommendations made at national and regional levels. However, information on the actions taken by local healthcare organizations regarding prescribing behaviour are limited and there is no evidence on how local authorities implement policy frameworks aimed at appropriately reallocating resources gained through patent expiration. Using Italy as a case study, with its decentralized healthcare system, authors investigated policies on biosimilars implemented at the local level in the Italian National Health Service.

In Italy, the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) supports the European Medicines Agency position on biosimilars. However, AIFA advises that the final decision on interchangeability is left to the prescriber. In Italy, Regional Health Authorities are responsible for planning healthcare services, allocating financial resources and pharmaceutical tendering. Local health authorities are responsible for implementing national and regional policies locally.

To investigate the implementation of policy at a local level, authors administered a structured, validated questionnaire, online to all of Italy’s 199 public health care authorities. They obtained responses from 76 organizations in 16 of 21 Italian regions. This showed that:
– 89% of local healthcare authorities implemented information/educational initiatives on biosimilars
– Prescription targets on biosimilars versus originators were introduced in 62% of local healthcare authorities
– Prescription targets on off-patent versus in-patent molecules were introduced in 75% of local healthcare authorities
– Prescribers reaching targets are mostly rewarded through monetary incentives
– 75% of local healthcare authorities performed systematic impact evaluation of biosimilars
– 21% of local healthcare authorities detected patient under-treatment due to budget constraints

These results reveal that, at a local level, there is a high level of proactivity by healthcare authorities regarding actions on prescribing behaviour for off-patent biologicals in Italy. However, the authors note that structured actions aimed at appropriately reallocating resources gained through patent expiration are still lacking.

GaBI Journal Citation Impact
1.9 – CiteScore 2020 (calculated on 5 May 2021)
1.6 – CiteScoreTracker 2021 (Last updated on 4 June 2021)

Submit a manuscript to GaBI Journal

Related articles
Italy simplifies over the counter generics price and reimbursement

Infliximab biosimilars for IBD patients experience from Italy

Biosimilars in Europe prescriber survey

Italy publishes new guidelines on pricing and reimbursement of generics and biosimilars

LATIN AMERICAN FORUM

The brand-new section the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. 

View this week’s headline article: Un nuevo decreto modifica varios aspectos del sistema de aprobación regulatoria de biosimilares en México

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Un nuevo decreto modifica varios aspectos del sistema de aprobación regulatoria de biosimilares en México

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

  
Reference
1. Bertolani A, Jommi C. Local policies on biosimilars: are they designed to optimize use of liberated resources? Generics and Biosimilars Initiative Journal (GaBI Journal). 2020;9(4):163-70. doi:10.5639/gabij.2020.0904.027

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
What drives negative perceptions of biosimilars?
11 AA010165
Biosimilars/Research Posted 23/07/2021
Clinical trials begin for ustekinumab biosimilars
T cell V21G23
Biosimilars/Research Posted 23/07/2021
Switching to biosimilars safe and effective in IBD patients
IBD 3
Biosimilars/Research Posted 16/07/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010